Art. -Nr.: HY-115735

SKI-I

Kundenbewertung

Based on 1 Customer Validation

SKI-I is a potent and selective inhibitor of human sphingosine kinase (SK), with an IC₅₀ of 1.2 μM for ST-hSK. SKI-I also inhibits hERK2 (IC₅₀=11 μM). SKI-I induces apoptosis in tumor cell lines.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.73%
CAS. Nr.: 306301-68-8
Formel: C₂₅H₁₈N₄O₂
Molecular Weight:406.44

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

SKI-I Chemical Structure

CAS. Nr.: 306301-68-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

IC50: 1.2 μM (ST-hSK); 11 μM (hERK2)^[1]

Alle SphK Isoform-spezifische Produkte anzeigen :

SphK1
SphK2

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	3.8 μM Compound: 4, SKI-I	Cytotoxicity against human A549 cells after 72 hrs by SRB assay Cytotoxicity against human A549 cells after 72 hrs by SRB assay	[PMID: 20598402]
HeLa	IC₅₀	1 μM Compound: 4, SKI-I	Cytotoxicity against human HeLa cells after 72 hrs by SRB assay Cytotoxicity against human HeLa cells after 72 hrs by SRB assay	[PMID: 20598402]
MCF-10A	IC₅₀	4.1 μM Compound: 4, SKI-I	Cytotoxicity against human MCF10A cells after 72 hrs by SRB assay Cytotoxicity against human MCF10A cells after 72 hrs by SRB assay	[PMID: 20598402]
MDA-MB-231	IC₅₀	4.4 μM Compound: 4, SKI-I	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 20598402]
MEF	IC₅₀	5 μM Compound: 4, SKI-I	Cytotoxicity against MEF after 72 hrs by SRB assay Cytotoxicity against MEF after 72 hrs by SRB assay	[PMID: 20598402]
MIA PaCa-2	IC₅₀	4.8 μM Compound: 4, SKI-I	Cytotoxicity against human MIAPaCa2 cells after 72 hrs by SRB assay Cytotoxicity against human MIAPaCa2 cells after 72 hrs by SRB assay	[PMID: 20598402]
NCI-H226	IC₅₀	5.7 μM Compound: 4, SKI-I	Cytotoxicity against human NCI-H226 cells after 72 hrs by SRB assay Cytotoxicity against human NCI-H226 cells after 72 hrs by SRB assay	[PMID: 20598402]
NCI-H441	IC₅₀	2 μM Compound: 4, SKI-I	Cytotoxicity against human H441 cells after 72 hrs by SRB assay Cytotoxicity against human H441 cells after 72 hrs by SRB assay	[PMID: 20598402]
NCI-H460	IC₅₀	3.2 μM Compound: 4, SKI-I	Cytotoxicity against human H460 cells after 72 hrs by SRB assay Cytotoxicity against human H460 cells after 72 hrs by SRB assay	[PMID: 20598402]
U-87MG ATCC	IC₅₀	1 μM Compound: 4, SKI-I	Cytotoxicity against human U87MG cells after 72 hrs by SRB assay Cytotoxicity against human U87MG cells after 72 hrs by SRB assay	[PMID: 20598402]

In Vitro

SKI-I (Compound I; 5 μg/mL) inhibits SK activity by 99%^[1].
SKI-I (10 μM; 24 h) induces the apoptosis of T24 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 306301-68-8
Appearance Solid
Molecular Weight 406.44
Formel C₂₅H₁₈N₄O₂
Color Off-white to light yellow
SMILES

O=C(C1=NNC(C2=CC=C3C=CC=CC3=C2)=C1)N/N=C/C4=C5C=CC=CC5=CC=C4O
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (246.04 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4604 mL

12.3019 mL

24.6039 mL

5 mM

0.4921 mL

2.4604 mL

4.9208 mL

10 mM

0.2460 mL

1.2302 mL

2.4604 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.15 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. French KJ, et, al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 2003 Sep 15;63(18):5962-9. [Content Brief]

[2]. Sharma AK, et, al. Synthesis and bioactivity of sphingosine kinase inhibitors and their novel aspirinyl conjugated analogs. Eur J Med Chem. 2010 Sep;45(9):4149-56. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.4604 mL	12.3019 mL	24.6039 mL	61.5097 mL
	5 mM	0.4921 mL	2.4604 mL	4.9208 mL	12.3019 mL
	10 mM	0.2460 mL	1.2302 mL	2.4604 mL	6.1510 mL
	15 mM	0.1640 mL	0.8201 mL	1.6403 mL	4.1006 mL
	20 mM	0.1230 mL	0.6151 mL	1.2302 mL	3.0755 mL
	25 mM	0.0984 mL	0.4921 mL	0.9842 mL	2.4604 mL
	30 mM	0.0820 mL	0.4101 mL	0.8201 mL	2.0503 mL
	40 mM	0.0615 mL	0.3075 mL	0.6151 mL	1.5377 mL
	50 mM	0.0492 mL	0.2460 mL	0.4921 mL	1.2302 mL
	60 mM	0.0410 mL	0.2050 mL	0.4101 mL	1.0252 mL
	80 mM	0.0308 mL	0.1538 mL	0.3075 mL	0.7689 mL
	100 mM	0.0246 mL	0.1230 mL	0.2460 mL	0.6151 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

SKI-I

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Anti-Cancer Compound Library

Heterocyclic Compound Library

Cysteine Targeted Covalent Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Bioactive Compound Library Max

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Alle SphK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

SKI-I

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Anti-Cancer Compound Library

Heterocyclic Compound Library

Cysteine Targeted Covalent Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Bioactive Compound Library Max

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Alle SphK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

SKI-I Related Classifications

HY-115735 Related Classifications